Literature DB >> 9546785

Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma.

C Rüegg1, A Yilmaz, G Bieler, J Bamat, P Chaubert, F J Lejeune.   

Abstract

Administration of tumor necrosis factor (TNF) and gamma interferon (IFN-gamma) to melanoma patients causes selective disruption of the tumor vasculature but the mechanism of this disruption is unknown. Here we report that exposure of human endothelial cells to TNF and IFN-gamma results in a reduced activation of integrin alphaVbeta3, an adhesion receptor that plays a key role in tumor angiogenesis, leading to a decreased alphaVbeta3-dependent endothelial cell adhesion and survival. Detachment and apoptosis of angiogenic endothelial cells was demonstrated in vivo in melanoma metastases of patients treated with TNF and IFN-gamma. These results implicate integrin alphaVbeta3 in the anti-vascular activity of TNF and IFN-gamma and demonstrate a new mechanism by which cytokines control cell adhesion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9546785     DOI: 10.1038/nm0498-408

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  77 in total

1.  Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway.

Authors:  K Nakatani; S Takeshita; H Tsujimoto; I Sekine
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 2.  Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.

Authors:  Alexander M M Eggermont; Timo L M ten Hagen
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

3.  Deflating the lymph node.

Authors:  Mingzhao Zhu; Yang-Xin Fu
Journal:  Immunity       Date:  2011-01-28       Impact factor: 31.745

4.  Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

Authors:  Ferdy J Lejeune
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 5.  Endothelial FAK as a therapeutic target in disease.

Authors:  Giovanni A Infusino; Jeffrey R Jacobson
Journal:  Microvasc Res       Date:  2011-10-06       Impact factor: 3.514

Review 6.  [Current state of neoadjuvant therapy of soft tissue sarcoma].

Authors:  M Lehnhardt; T Schmitt; M Bischof; A Daigeler; G Egerer
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

7.  Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.

Authors:  Steven K Libutti; Giulio F Paciotti; Adriana A Byrnes; H Richard Alexander; William E Gannon; Melissa Walker; Geoffrey D Seidel; Nargiza Yuldasheva; Lawrence Tamarkin
Journal:  Clin Cancer Res       Date:  2010-09-27       Impact factor: 12.531

8.  The expression and activity of MMPs are increased in residual tumor tissues after the termination of immunotherapy.

Authors:  Ting Xiong; Huimin Peng; Guoxi Chen; Ye Yuan
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

9.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs.

Authors:  M G van Ijken; E A de Bruijn; G de Boeck; T L ten Hagen; J R van der Sijp; A M Eggermont
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

10.  Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand.

Authors:  Paola Secchiero; Arianna Gonelli; Edvige Carnevale; Federica Corallini; Clara Rizzardi; Serena Zacchigna; Mauro Melato; Giorgio Zauli
Journal:  Neoplasia       Date:  2004 Jul-Aug       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.